206
Participants
Start Date
June 25, 2021
Primary Completion Date
January 30, 2025
Study Completion Date
January 30, 2025
Lomvastomig
2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
Tobemstomig
2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
Nivolumab
240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
Changhua Christian Hospital, Chang-hua
Rigshospitalet, København Ø
Odense Universitetshospital, Onkologisk Afdeling R, Odense C
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok
Dicle Uni Medical Faculty, Diyarbakır
National Taiwan University Hospital, Zhongzheng Dist.
Ramathibodi Hospital, Bangkok
Siriraj Hospital, Bangkok
Hopital Timone Adultes, Marseille
Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department, Erzurum
International Cancer Institute (ICI), Eldoret
Complejo Hospitalario de Navarra, Pamplona
Institut Bergonie, Bordeaux
Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della, Udine
Institut régional du Cancer Montpellier, Montpellier
IRCCS Istituto Oncologico Veneto (IOV), Padua
Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy
Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya
ICO Rene Gauducheau, Saint-Herblain
Hospital Clinico Universitario de Valencia, Valencia
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS, Meldola
Chonnam National University Hwasun Hospital, Jeollanam-do
Hopital Claude Huriez, Lille
Communal Non profit Enterprise Regional Center of Oncology, Kharkiv
Centre Leon Berard, Lyon
APHP - Hopital Saint Antoine, Paris
Songklanagarind Hospital, Songkhla
"Group of companies Medci", Moskva
Taipei Veterans General Hospital, Taipei
First Moscow State Medical University n.a. I.M. Sechenov, Moscow
MEDSI Clinical Hospital on Pyatnitsky Highway, Moscow
National Cancer Centre, Singapore
Curie Oncology, Singapore
Bashkirian Republican Clinical Oncology Dispensary, Ufa
Inst. Alexander Fleming, Buenos Aires
Centro Oncologico Riojano Integral (CORI), La Rioja
Hospital das Clinicas - UFRGS, Porto Alegre
Ac?badem Altunizade Hastanesi, Istanbul
Van Yuzuncu Yil University Hospital, Van
Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo
Masaryk?v onkologický ústav, Brno
Fakultni nemocnice Olomouc, Olomouc
Aga Khan University Hospital, Nairobi
Centrum Onkologii w Bydgoszczy, Bydgoszcz
Szpital Morski im. PCK, Gdynia
Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II, Krakow
NIO im Marii Sklodowskiej-Curie, Warsaw
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Hospital Clínic i Provincial, Barcelona
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital, Adana
Memorial Ankara Hastanesi, Ankara
Nottingham City Hospital, Nottingham
Hoffmann-La Roche
INDUSTRY